Moderna announced plans to expand its commercial presence in Asia by establishing four new subsidiaries in Malaysia, Taiwan, Singapore, and Hong Kong. This expansion reinforces Moderna's commitment to Asia and growing its global commercial operations. The new subsidiaries will support delivery of Moderna's mRNA vaccines and therapeutics locally. Moderna sees opportunities to address infectious diseases and other health challenges in Asia using its expanding mRNA technology portfolio.

1. NEWS RELEASE
Moderna Announces Plan to Expand Footprint in Asia
with Four Additional Subsidiaries
2/15/2022
Announcement reinforces Moderna's commitment to Asia and vision as a global commercial enterprise
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong; providing local presence to
support the delivery of mRNA vaccines and therapeutics
CAMBRIDGE, MA / ACCESSWIRE / February 15, 2022 / Moderna, Inc., (NASDAQ:MRNA), a biotechnology company
pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced plans to expand its commercial
network across Asia with the addition of four new subsidiaries in Malaysia, Taiwan, Singapore, and Hong Kong. This
expansion comes as the Company continues to scale up the manufacturing and distribution of its COVID-19 vaccine
and future mRNA vaccines and therapeutics.
The Asia-Paci c region represents an integral part of Moderna's business, with established subsidiaries in Japan,
South Korea, and Australia. In 2021, Moderna and the South Korean government announced a collaboration to
explore local opportunities for research and manufacturing in South Korea. More recently, the Company
announced an agreement in principle with the Australian Government to build a state-of-the-art mRNA vaccine
manufacturing facility in Victoria, Australia.
"2021 was a year of impact for Moderna, and I am proud to see continued growth in 2022 as we expand our
presence in Asia. After a decade of pioneering the development of our mRNA platform, we were ready to play a
critical role in combating the COVID-19 pandemic globally," said Stéphane Bancel, Chief Executive O cer of
Moderna. "With the addition of four subsidiaries in Asia, we look forward to new opportunities to leverage our
1

2. mRNA platform to help solve health challenges, including those with a high burden of disease in the Asia-Paci c
region."
Asia bears the highest burden of infectious diseases, and the burden of non-communicable diseases is increasing
as the population ages. Moderna's growing portfolio in prophylactic vaccines, cardiovascular diseases, oncology,
and rare diseases presents an unparalleled opportunity to use mRNA technology to maximize the potential impact
the Company can have on human health in the region.
Moderna's broader pipeline currently includes 40 development programs, of which 25 are in clinical trials. The
Company continues to update its COVID-19 strategy to address variants of concern such as Omicron and pioneer
new vaccines and therapeutics for a range of diseases and conditions. Moderna is developing mRNA medicines to
potentially prevent and treat diseases with signi cant unmet needs across infectious diseases, immuno-oncology,
rare and ultra-rare diseases, and autoimmune diseases.
Moderna currently has a presence in twelve markets globally. Regulators have approved Moderna's COVID-19
vaccine in more than 70 markets, including Canada, Japan, the European Union, the UK, and Israel. In 2021, 807
million doses of Moderna's COVID-19 vaccine were shipped globally, with approximately 25% of those doses
shipped to low- and middle-income markets.
About Moderna's Strategic Pillars
Moderna's has four strategic pillars guiding the Company's focus and impact for 2022 and beyond. Our strategic
pillars are:
Developing a pan-respiratory annual booster vaccine and continuously customizing it. A pan-respiratory
annual single booster vaccine covering multiple viruses, such as COVID-19, Flu, and Respiratory Syncytial
Virus, could create value for the healthcare system through compliance, convenience to the customer (one vs.
three injections), and reduction in vaccine administration cost
Developing rst-in-class vaccines against latent viruses for which there are no approved vaccines today.
Latent viruses infect the body, lay dormant, and do not replicate but possess the capacity to activate, causing
disease. In addition, new emerging evidence highlights that latent viral infections may have yet unknown
negative e ects. Moderna has clinical candidates in development for several latent viruses, including Epstein-
Barr Virus (Phase 1), human immunode ciency virus (Phase 1), and Cytomegalovirus (Phase 3)
Developing therapeutics based on mRNA-encoded proteins across oncology, cardiovascular, auto-immune
disorders, and rare genetic diseases
Developing therapeutics based on mRNA-encoded gene-editing enzymes
2

3. About Moderna
In 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in
the eld of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics
across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle
formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale
and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas
government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and
rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the approval of
one of the earliest and most e ective vaccines against the COVID-19 pandemic.
Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology
and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases,
immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. Moderna has been named a
top biopharmaceutical employer by Science for the past seven years. To learn more, visit www.modernatx.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, including regarding: the Company's plans to expand its commercial network
across Asia with the addition of four new subsidiaries in Hong Kong, Malaysia, Singapore, and Taiwan. The forward-
looking statements in this press release are neither promises nor guarantees, and you should not place undue
reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and
other factors, many of which are beyond Moderna's control and which could cause actual results to di er materially
from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors
include those other risks and uncertainties described under the heading "Risk Factors" in Moderna's most recent
Annual Report on Form 10-K led with the U.S. Securities and Exchange Commission (SEC) and in subsequent lings
made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by
law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements
contained in this press release in the event of new information, future developments or otherwise. These forward-
looking statements are based on Moderna's current expectations and speak only as of the date hereof.
Moderna Contacts
Media:
Luke Mircea Willats
Director, Corporate Communications
3

4. luke.mirceawillats@modernatx.com
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
View source version on accesswire.com:
https://www.accesswire.com/688880/Moderna-Announces-Plan-to-Expand-Footprint-in-Asia-with-Four-
Additional-Subsidiaries
4